NASDAQ:ESPR Esperion Therapeutics (ESPR) Stock Price, News & Analysis $0.95 +0.02 (+2.10%) Closing price 04:00 PM EasternExtended Trading$0.95 +0.00 (+0.19%) As of 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Esperion Therapeutics Stock (NASDAQ:ESPR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Esperion Therapeutics alerts:Sign Up Key Stats Today's Range$0.93▼$1.0650-Day Range$0.85▼$1.9052-Week Range$0.82▼$3.94Volume4.92 million shsAverage Volume5.65 million shsMarket Capitalization$187.80 millionP/E RatioN/ADividend YieldN/APrice Target$6.42Consensus RatingModerate Buy Company OverviewEsperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.Read More… Esperion Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks70th Percentile Overall ScoreESPR MarketRank™: Esperion Therapeutics scored higher than 70% of companies evaluated by MarketBeat, and ranked 260th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingEsperion Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 4 buy ratings, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageEsperion Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Esperion Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Esperion Therapeutics are expected to grow in the coming year, from ($0.29) to ($0.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Esperion Therapeutics is -1.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Esperion Therapeutics is -1.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Esperion Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.42% of the float of Esperion Therapeutics has been sold short.Short Interest Ratio / Days to CoverEsperion Therapeutics has a short interest ratio ("days to cover") of 6.4.Change versus previous monthShort interest in Esperion Therapeutics has recently decreased by 3.04%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEsperion Therapeutics does not currently pay a dividend.Dividend GrowthEsperion Therapeutics does not have a long track record of dividend growth. Sustainability and ESG3.9 / 5Environmental Score-2.76 Percentage of Shares Shorted14.42% of the float of Esperion Therapeutics has been sold short.Short Interest Ratio / Days to CoverEsperion Therapeutics has a short interest ratio ("days to cover") of 6.4.Change versus previous monthShort interest in Esperion Therapeutics has recently decreased by 3.04%, indicating that investor sentiment is improving. News and Social Media1.9 / 5News Sentiment0.39 News SentimentEsperion Therapeutics has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Esperion Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 8 people have searched for ESPR on MarketBeat in the last 30 days. This is a decrease of -62% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added Esperion Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -22% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Esperion Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,260.00 in company stock.Percentage Held by InsidersOnly 1.00% of the stock of Esperion Therapeutics is held by insiders.Percentage Held by Institutions47.39% of the stock of Esperion Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Esperion Therapeutics' insider trading history. Receive ESPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Esperion Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ESPR Stock News HeadlinesEsperion to Report First Quarter 2025 Financial Results on May 6April 23 at 12:34 PM | finance.yahoo.comEsperion Therapeutics, Inc. (ESPR) Stock ForecastsApril 23 at 7:34 AM | ca.finance.yahoo.comURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92% win rate trading system is built to profit in any market – whether Bitcoin is mooning, correcting, or chopping sideways. No more guessing. No more stress. Just precision trades that put you in control.April 23, 2025 | Crypto Swap Profits (Ad)Esperion Therapeutics Inc (ESPR) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ...April 21 at 9:02 PM | finance.yahoo.comThe Goldman Sachs Group Cuts Esperion Therapeutics (NASDAQ:ESPR) Price Target to $3.00April 20 at 3:37 AM | americanbankingnews.comEsperion to host R&D Day to highlight cardiometabolic pipelineApril 11, 2025 | markets.businessinsider.comEsperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025April 10, 2025 | globenewswire.comEsperion (ESPR) Gets a Buy from NeedhamApril 8, 2025 | markets.businessinsider.comSee More Headlines ESPR Stock Analysis - Frequently Asked Questions How have ESPR shares performed this year? Esperion Therapeutics' stock was trading at $2.20 at the start of the year. Since then, ESPR shares have decreased by 56.9% and is now trading at $0.9492. View the best growth stocks for 2025 here. How were Esperion Therapeutics' earnings last quarter? Esperion Therapeutics, Inc. (NASDAQ:ESPR) released its quarterly earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by $0.01. The biopharmaceutical company had revenue of $51.63 million for the quarter, compared to the consensus estimate of $55.44 million. Read the conference call transcript. Who are Esperion Therapeutics' major shareholders? Esperion Therapeutics' top institutional shareholders include Rhumbline Advisers (0.12%) and Synergy Asset Management LLC (0.02%). Insiders that own company stock include Benjamin Halladay, Sheldon L Koenig, Eric Warren, Joanne M Foody, Benjamin Looker and J Martin Carroll. View institutional ownership trends. How do I buy shares of Esperion Therapeutics? Shares of ESPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Esperion Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Esperion Therapeutics investors own include Humana (HUM), Voyager Therapeutics (VYGR), American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), Marinus Pharmaceuticals (MRNS) and AUO (AUOTY). Company Calendar Last Earnings11/07/2024Today4/23/2025Next Earnings (Estimated)5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ESPR CIK1434868 Webwww.esperion.com Phone(734) 887-3903FaxN/AEmployees200Year FoundedN/APrice Target and Rating Average Stock Price Target$6.42 High Stock Price Target$16.00 Low Stock Price Target$2.50 Potential Upside/Downside+589.7%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-209,250,000.00 Net Margins-29.37% Pretax Margin-29.37% Return on EquityN/A Return on Assets-10.77% Debt Debt-to-Equity RatioN/A Current Ratio1.85 Quick Ratio1.37 Sales & Book Value Annual Sales$332.31 million Price / Sales0.55 Cash FlowN/A Price / Cash FlowN/A Book Value($3.85) per share Price / Book-0.24Miscellaneous Outstanding Shares197,849,000Free Float195,065,000Market Cap$184.06 million OptionableOptionable Beta0.86 Social Links 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:ESPR) was last updated on 4/23/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Esperion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Esperion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.